ADCYAP1 and type 2 diabetes mellitus: The authors found that PACAP38 (0.6 and 60 pmol/kg/day, i.p.)administration at three weeks of age until 8 to 10 weeks reduced blood glucose in GK rats, an animal model of type 2 diabetes.